Selumetinib in children with recurrent or refractory low-grade glioma скачать в хорошем качестве

Selumetinib in children with recurrent or refractory low-grade glioma

Dr Fangusaro speaks with ecancer at ASCO 2017 about the results of a phase II multicentre prospective study of the efficacy of the MEK I/II inhibitor selumetinib in children with recurrent and refractory low-grade glioma. There was a 30-40% response rate in patients for whom multiple previous therapies had failed. He notes that selumetinib was fairly well tolerated by patients. The most common toxicities were Grade 1 and 2, and included nausea, diarrhoea, asymptomatic CPK elevation, rashes and paronychia. Other arms of the trial have been expanded based on results in the early groups. Dr Fangusaro is hopeful selumetinib will soon be used as a first-line therapy. The trial is conducted by the Paediatric Brain Tumour Consortium, an NCI funded group overseen by CTEP.